RecruitingPhase 3NCT06361537
Immune
Hereditary Angioedema
Also known as HAE, C1 inhibitor deficiency, HAE-C1-INH, bradykinin-mediated angioedema
Hereditary angioedema causes recurrent episodes of swelling in the skin, abdomen, and airway. Types 1 and 2 are caused by SERPING1 mutations leading to C1-inhibitor deficiency.
ORPHA:528623 ↗Gene SERPING1 (HAE types 1 and 2)Gene F12 (HAE-FXII)Prevalence 1-9 per 100,000 (Orphanet)Onset All agesGenetic (autosomal dominant)
4
studies recruiting now
as of 7 Sept 2026
41
studies registered in total
as of 7 Sept 2026
26
countries with a recruiting site
as of 7 Sept 2026
4 Mar 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT07266805
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
RecruitingNCT07448181
Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema
RecruitingPhase 1 / Phase 2NCT07046806
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
Showing the 4 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Hereditary Angioedema studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Hereditary Angioedema study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: US HAE Association Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Hereditary Angioedema
Hereditary angioedema causes recurrent episodes of swelling in the skin, abdomen, and airway. Types 1 and 2 are caused by SERPING1 mutations leading to C1-inhibitor deficiency. This allows unchecked bradykinin production, causing plasma leakage and swelling. Laryngeal attacks can be life-threatening. Multiple approved therapies exist including C1-INH concentrate, icatibant, lanadelumab, and berotralstat. Trial activity is high for new long-acting and gene-based approaches.
Common clinical features
Laryngeal edemaTongue edemaEdema of the dorsum of handsUrticariaDermatographic urticariaAbdominal painLimbal edemaRecurrent angioedema
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Hereditary Angioedema. Not eligibility rules; those are set by each study.
- HAE type (1, 2, or FXII) must be confirmed with C1-INH level, C1-INH function, and C4 tests
- Attack frequency (at least 3 attacks in 3 months is a common threshold) determines prophylaxis trial eligibility
- Current prophylactic therapy (lanadelumab, berotralstat) history affects enrollment in comparison trials
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).